Fig. 3From: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5LMean FACT-8D and EQ-5D-5L Crosswalk utility scores and standard errors by study visit for patients who completed the assessment at week 31 (n = 76 for ECOG0, n = 54 for ECOG1), based on baseline ECOG statusBack to article page